Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing.

"Declarations Ethics approval and consent to participateInformed consent was given in accordance with the Declaration of Helsinki and under approval from The First Affiliated Hospital of Zhengzhou University and The Affiliated Cancer Hospital of Zhengzhou University. Consent for publicationInformed consent has been obtained from the patient. Competing interestsThe authors declare that they have no competing interests relating to the publication of this manuscript. Competing interests The authors declare that they have no competing interests relating to the publication of this manuscript."

"Funding This work was supported by Natural Science Foundation of China (82270149, 82270141, 32100698, 82170211), China Postdoctoral Science Foundation (2022T150592, 2021M692930) and Young Postdoctoral Innovators in Henan Province (WL). Major Project of Henan Medical Science and Technology Research Plan (SBGJ202101007). Key research and development and promotion of special projects in Henan Province (222102310204). Henan Province Medical Science and Technology Research Project (SBGJ202102146, LHGJ20220305). Natural Science Foundation of Henan Province (222300420567). Outstanding Youth Fund of Henan Province (222300420068)."